404 related articles for article (PubMed ID: 14504831)
1. Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera.
Everaert H; Vanhove C; Lahoutte T; Muylle K; Caveliers V; Bossuyt A; Franken PR
Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1615-9. PubMed ID: 14504831
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2-dimensional and 3-dimensional acquisition for 18F-FDG PET oncology studies performed on an LSO-based scanner.
Lodge MA; Badawi RD; Gilbert R; Dibos PE; Line BR
J Nucl Med; 2006 Jan; 47(1):23-31. PubMed ID: 16391183
[TBL] [Abstract][Full Text] [Related]
3. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.
Halpern BS; Dahlbom M; Auerbach MA; Schiepers C; Fueger BJ; Weber WA; Silverman DH; Ratib O; Czernin J
J Nucl Med; 2005 Apr; 46(4):603-7. PubMed ID: 15809482
[TBL] [Abstract][Full Text] [Related]
4. Source of impaired image quality in 3D whole-body FDG PET scanning.
Paans AM; Boerdijk SM; Willemsen AT; Pruim J
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1207; author reply 1208. PubMed ID: 15197498
[No Abstract] [Full Text] [Related]
5. A lesion detection observer study comparing 2-dimensional versus fully 3-dimensional whole-body PET imaging protocols.
Lartizien C; Kinahan PE; Comtat C
J Nucl Med; 2004 Apr; 45(4):714-23. PubMed ID: 15073270
[TBL] [Abstract][Full Text] [Related]
6. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability.
Halpern BS; Dahlbom M; Quon A; Schiepers C; Waldherr C; Silverman DH; Ratib O; Czernin J
J Nucl Med; 2004 May; 45(5):797-801. PubMed ID: 15136629
[TBL] [Abstract][Full Text] [Related]
7. Defining optimal tracer activities in pediatric oncologic whole-body
Gatidis S; Schmidt H; la Fougère C; Nikolaou K; Schwenzer NF; Schäfer JF
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2283-2289. PubMed ID: 27565153
[TBL] [Abstract][Full Text] [Related]
8. Initial experience with a prototype dual-crystal (LSO/NaI) dual-head coincidence camera in oncology.
Joshi U; Hoekstra OS; Boellaard R; Comans EF; Raijmakers PG; Pijpers RJ; Miller SD; Teule GJ; van Lingen A
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):596-8. PubMed ID: 14722683
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
[TBL] [Abstract][Full Text] [Related]
10. Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET.
Tatsumi M; Clark PA; Nakamoto Y; Wahl RL
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):40-5. PubMed ID: 12483408
[TBL] [Abstract][Full Text] [Related]
11. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction.
Lonneux M; Borbath I; Bol A; Coppens A; Sibomana M; Bausart R; Defrise M; Pauwels S; Michel C
Eur J Nucl Med; 1999 Jun; 26(6):591-8. PubMed ID: 10369944
[TBL] [Abstract][Full Text] [Related]
12. Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose.
Masuda Y; Kondo C; Matsuo Y; Uetani M; Kusakabe K
J Nucl Med; 2009 Jun; 50(6):844-8. PubMed ID: 19443586
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of optimized injection dose and acquisition time using body mass index for three-dimensional whole-body FDG-PET].
Matsumoto K; Matsuura H; Minota E; Sakamoto S; Nakamoto Y; Senda M
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2004 Nov; 60(11):1564-73. PubMed ID: 15568009
[TBL] [Abstract][Full Text] [Related]
14. Integrated whole-body PET/MR hybrid imaging: clinical experience.
Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
[TBL] [Abstract][Full Text] [Related]
15. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images.
Bengel FM; Ziegler SI; Avril N; Weber W; Laubenbacher C; Schwaiger M
Eur J Nucl Med; 1997 Sep; 24(9):1091-8. PubMed ID: 9283100
[TBL] [Abstract][Full Text] [Related]
16. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET.
Visvikis D; Costa DC; Croasdale I; Lonn AH; Bomanji J; Gacinovic S; Ell PJ
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):344-53. PubMed ID: 12634961
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of the OS-EM algorithm and comparison with FBP for image reconstruction on a dual-head camera: a phantom and a clinical 18F-FDG study.
Gutman F; Gardin I; Delahaye N; Rakotonirina H; Hitzel A; Manrique A; Le Guludec D; Véra P
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1510-9. PubMed ID: 14579091
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of a short acquisition protocol for whole-body positron emission tomography with fluorine-18 fluorodeoxyglucose.
Paul AK; Tatsumi M; Fujino K; Hashikawa K; Nishimura T
Eur J Nucl Med; 2001 Nov; 28(11):1697-701. PubMed ID: 11702113
[TBL] [Abstract][Full Text] [Related]
19. The impact of acquisition time on image quality in whole-body 18F-FDG PET/CT for cancer staging.
Hausmann D; Dinter DJ; Sadick M; Brade J; Schoenberg SO; Büsing K
J Nucl Med Technol; 2012 Dec; 40(4):255-8. PubMed ID: 23071347
[TBL] [Abstract][Full Text] [Related]
20. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
